Molecular pathways in invasive bladder cancer

New insights into mechanisms, progression, and target identification

Anirban P. Mitra, Ram Datar, Richard J Cote

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by Interacting with the Ras-mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.

Original languageEnglish
Pages (from-to)5552-5564
Number of pages13
JournalJournal of Clinical Oncology
Volume24
Issue number35
DOIs
StatePublished - Dec 10 2006
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Retinoblastoma
Mitogen-Activated Protein Kinases
Epigenomics
Signal Transduction
Neoplasms
Cell Cycle
Clinical Trials
Oxygen
Carcinoma
Drug Therapy
Food
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Molecular pathways in invasive bladder cancer : New insights into mechanisms, progression, and target identification. / Mitra, Anirban P.; Datar, Ram; Cote, Richard J.

In: Journal of Clinical Oncology, Vol. 24, No. 35, 10.12.2006, p. 5552-5564.

Research output: Contribution to journalArticle

@article{843adc3b62164bedb38d3590b7a9f3ab,
title = "Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification",
abstract = "Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by Interacting with the Ras-mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.",
author = "Mitra, {Anirban P.} and Ram Datar and Cote, {Richard J}",
year = "2006",
month = "12",
day = "10",
doi = "10.1200/JCO.2006.08.2073",
language = "English",
volume = "24",
pages = "5552--5564",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Molecular pathways in invasive bladder cancer

T2 - New insights into mechanisms, progression, and target identification

AU - Mitra, Anirban P.

AU - Datar, Ram

AU - Cote, Richard J

PY - 2006/12/10

Y1 - 2006/12/10

N2 - Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by Interacting with the Ras-mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.

AB - Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by Interacting with the Ras-mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.

UR - http://www.scopus.com/inward/record.url?scp=34247337239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247337239&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.2073

DO - 10.1200/JCO.2006.08.2073

M3 - Article

VL - 24

SP - 5552

EP - 5564

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -